<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2022-11-4-240-245</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1382</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДОКЛИНИЧЕСКИЕ И КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRECLINICAL AND CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Апробация модели жировой дистрофии печени, индуцированной оротовой кислотой</article-title><trans-title-group xml:lang="en"><trans-title>Approbation of a Model of Fat Liver Disease Induced by Orotic Acid</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5783-8339</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковансков</surname><given-names>В. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovanskov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197376, г. Санкт-Петербург, ул. Проф. Попова, д. 14, лит. А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><email xlink:type="simple">vladislav.kovanskov@spcpu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9273-6864</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ивкин</surname><given-names>Д. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivkin</surname><given-names>D. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197376, г. Санкт-Петербург, ул. Проф. Попова, д. 14, лит. А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8464-7711</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семивеличенко</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Semivelichenko</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197376, г. Санкт-Петербург, ул. Проф. Попова, д. 14, лит. А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0869-3430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плиско</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Plisko</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197376, г. Санкт-Петербург, ул. Проф. Попова, д. 14, лит. А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2241-0724</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Копачёва</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kopacheva</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197376, г. Санкт-Петербург, ул. Проф. Попова, д. 14, лит. А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7573-1719</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сидоров</surname><given-names>К. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Sidorov</surname><given-names>K. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197376, г. Санкт-Петербург, ул. Проф. Попова, д. 14, лит. А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБОУ ВО «Санкт-Петербургский государственный химико-фармацевтический университет» Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России)<country>Россия</country></aff><aff xml:lang="en">St. Petersburg State Chemical and Pharmaceutical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>27</day><month>11</month><year>2022</year></pub-date><volume>11</volume><issue>4</issue><fpage>240</fpage><lpage>245</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ковансков В.Е., Ивкин Д.Ю., Семивеличенко Е.Д., Плиско Г.А., Копачёва Е.А., Сидоров К.О., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Ковансков В.Е., Ивкин Д.Ю., Семивеличенко Е.Д., Плиско Г.А., Копачёва Е.А., Сидоров К.О.</copyright-holder><copyright-holder xml:lang="en">Kovanskov V.V., Ivkin D.Y., Semivelichenko E.D., Plisko G.A., Kopacheva E.A., Sidorov K.O.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1382">https://www.pharmjournal.ru/jour/article/view/1382</self-uri><abstract><sec><title>Введение</title><p>Введение. Для терапии неалкогольной жировой болезни печени (НАЖБП) активно используют препараты-гепатопротекторы. Существующие модели неалкогольной жировой болезни печени, применяемые для изучения эффективности лекарственных препаратов, характеризуются большой длительностью воспроизведения и высокой смертностью тест-систем, в связи с чем актуальной задачей является апробация скрининговой модели данной патологии. В ряде исследований показана гепатотоксическая активность оротовой кислоты (ОК), видоспецифичная для крыс, приводящая к развитию НАЖБП.</p></sec><sec><title>Цель</title><p>Цель. Апробация модели НАЖБП, индуцированной оротовой кислотой на 2 видах грызунов (мыши и крысы), изучение обратимости патологии под действием референтного препарата (урсодезоксихолевая кислота – УДХК).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Исследование проведено на аутбредных крысах самцах массой 260–265 г (n = 21) и инбредных мышах самцах линии C57BL/6 массой 16–18 г (n = 30). Методом рандомизации крысы были разделены на 3 группы (по 7 крыс в каждой): 1-я группа – интактные животные; 2-я – модель НАЖБП; 3-я – модель НАЖБП + УДХК; мыши были разделены на 2 группы (по 10 и 20 мышей соответственно): 1-я группа – интактные животные; 2-я – модель НАЖБП. НАЖБП моделировали высокоуглеводной диетой с оротовой кислотой (75 % стандартный корм, 24 % фруктозы и 1 % оротата калия). УДХК вводили после первой контрольной точки 1 раз в день через зонд в пересчете 150 мг/кг. Проведено биохимическое и гистологическое исследование.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Выявлено, что высокоуглеводная диета с добавлением 1 % оротата калия в течение 4 недель вызывает средневыраженную баллонную дистрофию, слабовыраженный гепатит и увеличение содержания аланинаминотрансферазы и аспартатаминотрансферазы в крови у крыс и менее значимые изменения у мышей. Также отмечена низкая смертность животных. Применение УДХК на заявленной модели вызывает уменьшение выраженности дистрофии печени и снижение уровня печеночных ферментов в крови.</p></sec><sec><title>Заключение</title><p>Заключение. На основании проведенных экспериментов оптимальной тест-системой на воспроизведенной модели оказались крысы, а высокожировая диета с добавлением оротовой кислоты позволяет осуществлять скрининговые исследования препаратов с гепатотропной активностью.  </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. For the treatment of non-alcoholic fatty liver disease (NAFLD), hepatoprotective drugs are actively used. The existing models of non-alcoholic fatty liver disease used to study the effectiveness of medicinal products are characterized by a long duration of recovery and high mortality of test systems, in connection with which, the actual task is to test the screening model of this pathology. A number of studies have shown the hepatotoxic activity of orotic acid (OK), species-specific for rats, leading to the development of NAFLD.</p></sec><sec><title>Aim</title><p>Aim. Approbation of the NAFLD model induced by orotic acid on 2 rodent species (mice and rats), research of the reversibility of pathology under the action of a reference drug (ursodeoxycholic acid – UDCA).</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The reseacrh was conducted on outbred male rats weighing 260–265 g (n = 21) and inbred male mice of the C57BL/6 line weighing 16–18 g (n = 30). By randomization, the rats were divided into 3 groups (7 rats each): group 1 – intact animals; group 2 – NAFLD model; group 3 – NAFLD + UDCA model, mice were divided into 2 groups (10 and 20 mice, respectively): group 1 – intact animals; group 2 – NAFLD model. NAFLD was modeled by a high-carbohydrate diet with orotic acid (75 % standard feed, 24 % fructose and 1 % potassium orotate). UDCA was administered after the first control point 1 time a day through a probe in terms of 150 mg/kg. Biochemical and histological examination was carried out.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. It was revealed that a high-carbohydrate diet with the addition of 1 % potassium orotate for 4 weeks causes moderate balloon dystrophy, mild hepatitis and an increase in the content of alanine aminotransferase and aspartate aminotransferase in the blood of rats and less significant changes in mice. Low animal mortality was also noted. The use of UDCA on the claimed model causes a decrease in the severity of liver dystrophy and a decrease in the level of liver enzymes in the blood.</p></sec><sec><title>Conclusion</title><p>Conclusion. Based on the conducted experiments, rats turned out to be the optimal test system on the reproduced model, and a high-fat diet with the addition of orotic acid allows screening studies of drugs with hepatotropic activity.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>НАЖБП</kwd><kwd>урсодезоксихолевая кислота</kwd><kwd>аланинаминотрансфераза</kwd><kwd>аспартатаминотрансфераза</kwd><kwd>баллонная дистрофия</kwd><kwd>гепатит</kwd></kwd-group><kwd-group xml:lang="en"><kwd>NAFLD</kwd><kwd>ursodeoxycholic acid</kwd><kwd>alanine aminotransferase</kwd><kwd>aspartate-minotransferase</kwd><kwd>balloon dystrophy</kwd><kwd>hepatitis</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Результаты работы получены с использованием ресурсов ЦКП «Аналитический центр ФГБОУ ВО СПХФУ Минздрава России» в рамках соглашения № 075-15-2021-685 от 26 июля 2021 года при финансовой поддержке Минобрнауки России.</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>The results of the work were obtained using the resources of the Center for Collective Use "Analytical Center of the Federal State Budgetary Educational Institution of Higher Education Saint-Petersburg State Chemical-Pharmaceutical University of the Ministry of Health of Russia" within the framework of agreement No. 075-15-2021-685 dated July 26, 2021 with the financial support of the Ministry of Education and Science of Russia.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Younossi Z., Anstee Q. M., Marietti M., Hardy T., Henry L., Eslam M. Global burden of NAFLD and NASH: trends, predictions, risk factors andprevention. Nature Reviews Gastroenterology and Hepatology. 2018;15:11–20. DOI: 10.1038/nrgastro.2017.109.</mixed-citation><mixed-citation xml:lang="en">Younossi Z., Anstee Q. M., Marietti M., Hardy T., Henry L., Eslam M. Global burden of NAFLD and NASH: trends, predictions, risk factors andprevention. Nature Reviews Gastroenterology and Hepatology. 2018;15:11–20. DOI: 10.1038/nrgastro.2017.109.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Буеверов А. О., Богомолов П. О., Маевская М. В. Патогенетическое лечение неалкогольного стеатогепатита: обоснование, эффективность, безопасность. Терапевтический архив. 2007;79(8):1–4.</mixed-citation><mixed-citation xml:lang="en">Bueverov A. O., Bogomolov P. O., Maevskaya M. V. Pathogenetic treatment of non-alcoholic steatohepatitis: rationale, efficacy, safety. Therapeutic archive. 2007;79(8):1–4. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chang M., Zhang T., Han X., Tang Q., Yanagita T., Xu J., Xue C. Wang Y. Comparative Analysis of EPA/DHA-PL Forage and Liposomes in Orotic Acid-Induced Nonalcoholic Fatty Liver Rats and Their Related Mechanisms. Journal of Agricultural and Food Chemistry. 2018;66(6):1408–1418. DOI: 10.1021/acs.jafc.7b05173.</mixed-citation><mixed-citation xml:lang="en">Chang M., Zhang T., Han X., Tang Q., Yanagita T., Xu J., Xue C. Wang Y. Comparative Analysis of EPA/DHA-PL Forage and Liposomes in Orotic Acid-Induced Nonalcoholic Fatty Liver Rats and Their Related Mechanisms. Journal of Agricultural and Food Chemistry. 2018;66(6):1408–1418. DOI: 10.1021/acs.jafc.7b05173.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y., Shi D., Tian Y., Liu Y., Zhan Q., Xu J., Wang J., Xue C. Eicosapentaenoic Acid-Enriched Phosphatidylcholine Attenuated Hepatic Steatosis Through Regulation of Cholesterol Metabolism in Rats with Nonalcoholic Fatty Liver Disease. Lipids. 2017;52(2):119–127. DOI: 10.1007/s11745-016-4222-1.</mixed-citation><mixed-citation xml:lang="en">Liu Y., Shi D., Tian Y., Liu Y., Zhan Q., Xu J., Wang J., Xue C. Eicosapentaenoic Acid-Enriched Phosphatidylcholine Attenuated Hepatic Steatosis Through Regulation of Cholesterol Metabolism in Rats with Nonalcoholic Fatty Liver Disease. Lipids. 2017;52(2):119–127. DOI: 10.1007/s11745-016-4222-1.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bunjat A., Spasenkova O., Karev V., Karavaeva A. V., Ivkin D., Kulikov A., Okovityi S., Kirillova N. Modification of a model of non-alcoholic fatty liver disease in rats with a combination of a hypercaloric diet and hypodynamia. Pharmaceutical Medicine. 2021;10:155–165. DOI: 10.33380/2305-2066-2021-10-4(1)-155-165.</mixed-citation><mixed-citation xml:lang="en">Bunjat A., Spasenkova O., Karev V., Karavaeva A. V., Ivkin D., Kulikov A., Okovityi S., Kirillova N. Modification of a model of non-alcoholic fatty liver disease in rats with a combination of a hypercaloric diet and hypodynamia. Pharmaceutical Medicine. 2021;10:155–165. DOI: 10.33380/2305-2066-2021-10-4(1)-155-165.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Суханов Д. С., Ивкин Д. Ю., Плиско Г. А., Караваева А. В., Краснова М. В., Поверяева М. А., Карев В. Е., Бунят А. В., Степанова И. Л., Оковитый С. В. Влияние производного 2-этил-6-метил-3-гидроксипиридина на течение неалкогольной жировой болезни в печени. Молекулярная медицина. 2020;18(1):23–25.</mixed-citation><mixed-citation xml:lang="en">Sukhanov D. S., Ivkin D. Yu., Plisko G. A., Karavaeva A. V., Krasnova M. V., Poveryaeva M. A., Karev V. E., Bunyat A. V., Stepanova I. L., Okovity S. V. Influence of 2-ethyl-6-methyl-3-hydroxypyridine derivative on the course of non-alcoholic fatty liver disease. Molecular Medicine. 2020;18(1):23–25. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zhengri L., Song H. L., Hee J. J., Hee E. K. Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid. Xenobiotica. 2021;51(3):324–334. DOI: 10.1080/00498254.2020.1851070.</mixed-citation><mixed-citation xml:lang="en">Zhengri L., Song H. L., Hee J. J., Hee E. K. Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid. Xenobiotica. 2021;51(3):324–334. DOI: 10.1080/00498254.2020.1851070.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Han X., Liu C., Xue Y., Wang J., Xue C., Yanagita T., Gao X., Wang Y. Long-term fatty liver-induced insulin resistance in orotic acid-induced nonalcoholic fatty liver rats. Bioscience, Biotechnology and Biochemistry. 2017;80(4):735–743. DOI: 10.1080/09168451.2015.1123608.</mixed-citation><mixed-citation xml:lang="en">Han X., Liu C., Xue Y., Wang J., Xue C., Yanagita T., Gao X., Wang Y. Long-term fatty liver-induced insulin resistance in orotic acid-induced nonalcoholic fatty liver rats. Bioscience, Biotechnology and Biochemistry. 2017;80(4):735–743. DOI: 10.1080/09168451.2015.1123608.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rinella M., Cryer D. R., Articolo A., Fisher T., Schneider J., Nadolsky K. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterology. 2022;22(1):335. DOI: 10.1186/s12876-022-02410-x.</mixed-citation><mixed-citation xml:lang="en">Rinella M., Cryer D. R., Articolo A., Fisher T., Schneider J., Nadolsky K. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterology. 2022;22(1):335. DOI: 10.1186/s12876-022-02410-x.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang Z., Kimura Y., Shirouchi B., Yuan X., Sato M. Dietary egg white protein hydrolysate improves orotic acid-induced fatty liver in rats by promoting hepatic phospholipid synthesis and microsomal triglyceride transfer protein expression. Journal of Nutritional Biochemistry. 2021;98:108820. DOI: 10.1016/j.jnutbio.2021.108820.</mixed-citation><mixed-citation xml:lang="en">Jiang Z., Kimura Y., Shirouchi B., Yuan X., Sato M. Dietary egg white protein hydrolysate improves orotic acid-induced fatty liver in rats by promoting hepatic phospholipid synthesis and microsomal triglyceride transfer protein expression. Journal of Nutritional Biochemistry. 2021;98:108820. DOI: 10.1016/j.jnutbio.2021.108820.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hu Y., Xu J., Chen Q., Zhang Y., Wang T. Regulation effects of total flavonoids in Morus alba L. On hepatic cholesterol disorders in orotic acid induced NAFLD rats. BMC Complementary Medicine and Therapies. 2020;20(117):257. DOI: 10.1186/s12906-020-03052-w.</mixed-citation><mixed-citation xml:lang="en">Hu Y., Xu J., Chen Q., Zhang Y., Wang T. Regulation effects of total flavonoids in Morus alba L. On hepatic cholesterol disorders in orotic acid induced NAFLD rats. BMC Complementary Medicine and Therapies. 2020;20(117):257. DOI: 10.1186/s12906-020-03052-w.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Subali D., Kwon M. H., Bang W. S., Kang H. E. The pharmacokinetics of mycophenolic acid in rats with orotic acid induced nonalcoholic fatty liver disease. Canadian Journal of Physiology and Pharmacology. 2020;98(3):169–176. DOI: 10.1139/cjpp-2019-0383.</mixed-citation><mixed-citation xml:lang="en">Subali D., Kwon M. H., Bang W. S., Kang H. E. The pharmacokinetics of mycophenolic acid in rats with orotic acid induced nonalcoholic fatty liver disease. Canadian Journal of Physiology and Pharmacology. 2020;98(3):169–176. DOI: 10.1139/cjpp-2019-0383.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bang W. S., Hwang Y. R., Li Z., Lee I., Kang H. E. Effects of orotic acid-induced non-alcoholic fatty liver on the pharmacokinetics of metoprolol and its metabolites in rats. Journal of Pharmacy and Pharmaceutical Sciences. 2020;22:98–111. DOI: 10.18433/jpps30268.</mixed-citation><mixed-citation xml:lang="en">Bang W. S., Hwang Y. R., Li Z., Lee I., Kang H. E. Effects of orotic acid-induced non-alcoholic fatty liver on the pharmacokinetics of metoprolol and its metabolites in rats. Journal of Pharmacy and Pharmaceutical Sciences. 2020;22:98–111. DOI: 10.18433/jpps30268.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Губергриц Б., Лукашевич Г. М., Фоменко П. Г. Гепатопротекторы: от теории к практике. М.: 4ТЕ Арт; 2012. 52 с.</mixed-citation><mixed-citation xml:lang="en">Gubergrits B., Lukashevich G. M., Fomenko P. G. Hepatoprotectors: from theory to practice. Moscow: 4TE Art; 2012. 52 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Freireich E. J., Gehan E. A., Rail D. P., Schmidt L. H., Skipper H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50(4):219–244.</mixed-citation><mixed-citation xml:lang="en">Freireich E. J., Gehan E. A., Rail D. P., Schmidt L. H., Skipper H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50(4):219–244.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Jung E. J., Kwon S. W., Jung B. H., Oh S. H., Lee B. H. Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liver. Jlr Res. 2011;52(9):1617–1625. DOI: 10.1194/jlr.M015263.</mixed-citation><mixed-citation xml:lang="en">Jung E. J., Kwon S. W., Jung B. H., Oh S. H., Lee B. H. Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liver. Jlr Res. 2011;52(9):1617–1625. DOI: 10.1194/jlr.M015263.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
